Fuzuloparib

Fuzuloparib - Names and Identifiers

Name	4-(4-fluoro-3-(2-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine-7-carbonyl)benzyl)phthalazin-1(2H)-one
Synonyms	HS10160 Fuzuopali Fluzoparib Fuzuloparib 4-(4-fluoro-3-(2-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine-7-carbonyl)benzyl)phthalazin-1(2H)-one 1(2H)-Phthalazinone, 4-[[3-[[5,6-dihydro-2-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]carbonyl]-4-fluorophenyl]methyl]-
CAS	1358715-18-0

Fuzuloparib - Physico-chemical Properties

Molecular Formula	C22H16F4N6O2
Molar Mass	472.4
Solubility	Soluble in DMSO
Storage Condition	-20℃
Use	Fuzuopali is a poly (ADP-ribose) polymerase inhibitor (PARP) inhibitor potentially for the treatment of solid tumours.

Fuzuloparib - Reference

Reference

1: Jiang X, Tao Y, Liu Y, Shi P, Li T, Sun F, Cao Y, Wang C. A Randomized, Open- label, Two-period Crossover Bridging Study on Fuzuloparib Capsules of Different Specifications in Healthy Chinese Volunteers. Br J Clin Pharmacol. 2021 Aug 10. doi: 10.1111/bcp.15035. Epub ahead of print. PMID: 34378245.
2: Lee A. Correction to: Fuzuloparib: First Approval. Drugs. 2021 Jul;81(10):1227. doi: 10.1007/s40265-021-01570-6. Erratum for: Drugs. 2021 Jul;81(10):1221-1226. PMID: 34245448.
3: Lee A. Fuzuloparib: First Approval. Drugs. 2021 Jul;81(10):1221-1226. doi: 10.1007/s40265-021-01541-x. Erratum in: Drugs. 2021 Jul 10;: PMID: 34118019.
4: Zhang Q, Kai J, Zhai Y, Xu N, Shentu J, Zhang Y, Liang Y, Wang Y, Wu L. The impact of rifampicin on the pharmacokinetics of fuzuloparib in healthy Chinese male volunteers. Br J Clin Pharmacol. 2021 May 25. doi: 10.1111/bcp.14926. Epub ahead of print. PMID: 34033139.

Fuzuloparib - Preparation solution concentration reference

	1mg	5mg	10mg
1 mM	2.117 ml	10.584 ml	21.168 ml
5 mM	0.423 ml	2.117 ml	4.234 ml
10 mM	0.212 ml	1.058 ml	2.117 ml
5 mM	0.042 ml	0.212 ml	0.423 ml

Last Update：2024-01-02 23:10:35

Fuzuloparib - Reference Information

biological activity	Fluzoparib(SHR3162,HS10160) is a potent Poly (ADP-ribose) polymer (PARP) inhibitors, with anti-tumor activity.
Target	TargetValue PARP ()
Target	Value

Last Update：2024-04-10 22:29:15